{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumour+of+the+Lung&page=5", "query": { "condition": "Neuroendocrine Tumour of the Lung", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 274, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumour+of+the+Lung&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumour+of+the+Lung&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T02:15:09.487Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04752267", "title": "18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Glioma", "Malignant Brain Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Kidney Carcinoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "18F-FMAU", "type": "DRUG" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-02-15", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752267" }, { "nct_id": "NCT07160335", "title": "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "HLX17", "type": "DRUG" }, { "name": "US-sourced Keytruda®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 174, "start_date": "2025-09-26", "completion_date": "2028-03-27", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 12, "location_summary": "Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07160335" }, { "nct_id": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Acral Lentiginous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Melanoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Epithelial Ovarian Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "ATRC-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Atreca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-02-11", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04244552" }, { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT02948946", "title": "Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor", "Lung Neuroendocrine Neoplasm" ], "interventions": [ { "name": "NETest", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2017-01-09", "completion_date": "2020-09-15", "has_results": false, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948946" }, { "nct_id": "NCT02054104", "title": "Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Thoracic Sarcomas", "Thorasic Cancers", "Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura", "Sarcoma", "Melanoma" ], "interventions": [ { "name": "H1299 cell lysates", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Iscomatrix adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-09-03", "completion_date": "2015-06-15", "has_results": true, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02054104" }, { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2021-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT04291079", "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "SRK-181", "type": "BIOLOGICAL" }, { "name": "anti-PD-(L)1 antibody therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Scholar Rock, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2020-04-23", "completion_date": "2025-04-14", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 18, "location_summary": "Fullerton, California • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291079" }, { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT05619744", "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "RO7616789", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-01-23", "completion_date": "2025-03-04", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-13T02:15:09.487Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05619744" } ] }